Overview
An Observational Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) And Oxaliplatin in Patients With Colorectal Cancer
Status:
Completed
Completed
Trial end date:
2014-02-01
2014-02-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
This prospective observational study will evaluate the efficacy and safety of bevacizumab in combination with capecitabine and oxaliplatin as first-line treatment in participants with colorectal cancer. Data will be collected from each participant until disease progression occurs (for up to 30 months).Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Hoffmann-La RocheTreatments:
Bevacizumab
Capecitabine
Oxaliplatin
Criteria
Inclusion Criteria:- Adult patients, >/= 18 years of age
- Metastatic colorectal cancer
- Treatment in accordance with current Summary of Product Characteristics and local
guidelines
Exclusion Criteria:
- Contraindications according to current Summary of Product Characteristics and local
guidelines